
Cystic Fibrosis - Pipeline Insight, 2025
Description
DelveInsight’s, “Cystic Fibrosis - Pipeline Insight, 2025,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Cystic Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cystic Fibrosis: Overview
Cystic fibrosis (CF) is a genetic condition that affects a protein in the body. People who have cystic fibrosis have a faulty protein that affects the body’s cells, tissues, and the glands that make mucus and sweat. Mucus is normally slippery and protects the linings of the airways, digestive tract, and other organs and tissues. People who have cystic fibrosis make thick, sticky mucus that can build up and lead to blockages, damage, or infections in the affected organs. Inflammation also causes damage to organs such as the lungs and pancreas. Some people who have cystic fibrosis have few or no signs or symptoms, while others experience severe symptoms or life-threatening complications. Symptoms of cystic fibrosis depend on which organs are affected and the severity of the condition. The most serious and common complications of cystic fibrosis are problems with the lungs, also known as pulmonary or respiratory problems, which may include serious lung infections. People who have cystic fibrosis often also have problems maintaining good nutrition, because they have a hard time absorbing the nutrients from food. This is a problem that can delay growth.
""Cystic Fibrosis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cystic Fibrosis pipeline landscape is provided which includes the disease overview and Cystic Fibrosis treatment guidelines. The assessment part of the report embraces, in depth Cystic Fibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystic Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Cystic Fibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cystic Fibrosis Emerging Drugs
Further product details are provided in the report……..
Cystic Fibrosis: Therapeutic Assessment
This segment of the report provides insights about the different Cystic Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:
Cystic Fibrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cystic Fibrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cystic Fibrosis drugs.
Cystic Fibrosis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Cystic Fibrosis: Overview
Cystic fibrosis (CF) is a genetic condition that affects a protein in the body. People who have cystic fibrosis have a faulty protein that affects the body’s cells, tissues, and the glands that make mucus and sweat. Mucus is normally slippery and protects the linings of the airways, digestive tract, and other organs and tissues. People who have cystic fibrosis make thick, sticky mucus that can build up and lead to blockages, damage, or infections in the affected organs. Inflammation also causes damage to organs such as the lungs and pancreas. Some people who have cystic fibrosis have few or no signs or symptoms, while others experience severe symptoms or life-threatening complications. Symptoms of cystic fibrosis depend on which organs are affected and the severity of the condition. The most serious and common complications of cystic fibrosis are problems with the lungs, also known as pulmonary or respiratory problems, which may include serious lung infections. People who have cystic fibrosis often also have problems maintaining good nutrition, because they have a hard time absorbing the nutrients from food. This is a problem that can delay growth.
""Cystic Fibrosis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cystic Fibrosis pipeline landscape is provided which includes the disease overview and Cystic Fibrosis treatment guidelines. The assessment part of the report embraces, in depth Cystic Fibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystic Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cystic Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Cystic Fibrosis.
This segment of the Cystic Fibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cystic Fibrosis Emerging Drugs
- VX-121: Vertex Pharmaceuticals
- Brensocatib: AstraZeneca
- ELX-02: Eloxx Pharmaceuticals
- S-1226: SolAeroMed Inc.
Further product details are provided in the report……..
Cystic Fibrosis: Therapeutic Assessment
This segment of the report provides insights about the different Cystic Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cystic Fibrosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Cystic Fibrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cystic Fibrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cystic Fibrosis drugs.
Cystic Fibrosis Report Insights
- Cystic Fibrosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cystic Fibrosis drugs?
- How many Cystic Fibrosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cystic Fibrosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cystic Fibrosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cystic Fibrosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eloxx Pharmaceuticals
- Arrowhead Pharmaceuticals
- SolAeroMed
- Parion Sciences
- Translate Bio, Inc.
- Path BioAnalytics
- Aridis Pharmaceuticals
- Novartis
- Vertex Pharmaceuticals
- AlgiPharma
- Proteostasis Therapeutics, Inc.
- Galapagos NV
- Santhera Pharmaceuticals
- Calithera Biosciences, Inc
- Spyryx Biosciences, Inc.
- Verona Pharma
- Ionis Pharmaceuticals, Inc.
- Chiesi Farmaceutici S.p.A.
- Ligand Pharmaceuticals
- Boehringer Ingelheim
- OrPro Therapeutics
- Protalix Biotherapeutics
- Laurent Pharmaceuticals
- Arcturus Therapeutics
- Enterprise Therapeutics
- Affinia Therapeutics
- AlgiPharma AS
- Sound Pharmaceuticals
- Spirovant
- 4D Molecular Therapeutics
- Santhera Pharmaceuticals
- Armata Pharmaceuticals
- ELX-02
- NM002
- ARO ENaC
- S-1226
- P-1037
- MRT5005
- Cavosonstat
- AR-501
- QBW276
- VX-121
- OligoG
- PTI-808
- JBT-101
- GLPG1837
- POL6014
- CB-280
- Galicaftor
- SPX-101
- RPL554
- LAU-7b
- IONIS-ENaCRx
- CHF 6333
- Theradux
- PRX 110
- LAU-7b
- LUNAR-CF
- ETD001
- 4D-710
- AP-PA02
Table of Contents
200 Pages
- Introduction
- Executive Summary
- Cystic Fibrosis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
- Comparative Analysis
- VX-121: Vertex Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ELX-02: Eloxx Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- ARO ENaC: Translate Bio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Cystic Fibrosis Key Companies
- Cystic Fibrosis Key Products
- Cystic Fibrosis- Unmet Needs
- Cystic Fibrosis- Market Drivers and Barriers
- Cystic Fibrosis- Future Perspectives and Conclusion
- Cystic Fibrosis Analyst Views
- Cystic Fibrosis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.